Results 211 to 220 of about 240,351 (245)
Some of the next articles are maybe not open access.
Cancer Research, 2005
Abstract Interleukin 6 (IL-6) is a multifunctional and pleiotropic cytokine and in renal cell carinoma (RCC), this cytokine exerts proinflammatory, immunosuppressive and growth stimulating properties. A spliced isoform of IL-6 mRNA has been described in peripheral blood mononuclear cells and encodes for a potential protein lacking IL-6 ...
Laurent, Alberti +4 more
openaire +2 more sources
Abstract Interleukin 6 (IL-6) is a multifunctional and pleiotropic cytokine and in renal cell carinoma (RCC), this cytokine exerts proinflammatory, immunosuppressive and growth stimulating properties. A spliced isoform of IL-6 mRNA has been described in peripheral blood mononuclear cells and encodes for a potential protein lacking IL-6 ...
Laurent, Alberti +4 more
openaire +2 more sources
Tocilizumab: The first interleukin-6-receptor inhibitor
American Journal of Health-System Pharmacy, 2008The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed.Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R).
openaire +2 more sources
Plasminogen activator inhibitor type‐1 and interleukin‐6 in haemolytic uraemic syndrome
Journal of Paediatrics and Child Health, 2000Objective: Because haemolytic uraemic syndrome (HUS) is an important cause of renal dysfunction in children, the availability of prognostic markers of disease severity could assist in identifying those at risk of developing long‐term sequelae. The aim of this study was to test the hypothesis that plasma levels of plasminogen activator inhibitor type‐1
A A, Martin +6 more
openaire +2 more sources
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
European Journal of Biochemistry, 2001Signal transduction in response to interleukin‐6 (IL‐6) requires binding of the cytokine to its receptor (IL‐6R) and subsequent homodimerization of the signal transducer gp130. The complex of IL‐6 and soluble IL‐6R (sIL‐6R) triggers dimerization of gp130 and induces responses on cells that do not express membrane bound IL‐6R.
T, Jostock +8 more
openaire +2 more sources
Molecular and Cellular Endocrinology, 1995
Interleukin-6 bioactivity (IL-6) has been shown to be present in Sertoli cells. To further characterize the IL-6 in the seminiferous epithelium, the IL-6 like-antigen was detected, stage-specific basal distribution of IL-6-like bioactivity and its regulation by FSH, cAMP and TPA was characterized in isolated, rat seminiferous tubule segments.
H, Hakovirta +3 more
openaire +2 more sources
Interleukin-6 bioactivity (IL-6) has been shown to be present in Sertoli cells. To further characterize the IL-6 in the seminiferous epithelium, the IL-6 like-antigen was detected, stage-specific basal distribution of IL-6-like bioactivity and its regulation by FSH, cAMP and TPA was characterized in isolated, rat seminiferous tubule segments.
H, Hakovirta +3 more
openaire +2 more sources
Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice
Gut, 2008Background and aims Interleukin-6 (IL-6) is a well-recognised mediator of liver disease and regeneration. However, the in vivo effects of IL-6 on enterocytes and the intestinal tract have not been elucidated. We sought to determine the in vivo effects of IL-6 on enterocytes.
Xiaoling, Jin +4 more
openaire +2 more sources
Intravitreal Interleukin 6 Inhibitors for Uveitic Macular Edema
JAMA OphthalmologyThis Viewpoint discusses the results of a phase 1 study evaluating the intravitreal interleukin 6 inhibitor vamikibart for the treatment of uveitic macular edema.
Stephanie M. Llop, Swati L. Narayan
openaire +1 more source
Recurrent hypofibrinogenemia with interleukin-6 inhibitors tocilizumab and sarilumab: A case report
Journal of Hematology and Allied SciencesHypofibrinogenemia is a rare but clinically significant adverse effect of interleukin-6 (IL-6) receptor blockade, most associated with tocilizumab. We present a case of recurrent hypofibrinogenemia in an elderly patient with seronegative rheumatoid arthritis who developed bleeding complications during tocilizumab therapy and subsequently experienced ...
Amir Warwar +3 more
openaire +1 more source